Document is current
Any future updates will be listed below
-
Authors
Lingham, Gareth https://orcid.org/0000-0002-8957-0733
Loughman, James
Lee, Samantha SY https://orcid.org/0000-0001-6635-1098
Repka, Michael X.
Kerin, Eoin https://orcid.org/0009-0004-8474-8856
Gómez Sánchez, Alicia
Kobia-Acquah, Emmanuel
Nkansah, Ernest Kyei
Flitcroft, Ian https://orcid.org/0000-0002-7004-6026
Mackey, David A.
-
Funding
Funding for this research was provided by:
Channel 7 Telethon Trust
Health Research Board (MRCG 2016-03)
The Ophthalmic Research Institute of Australia
University of Western Australia
Fighting Blindness (Ireland), Healy Medical Research Foundation, Vyluma
Perron Foundation Health Research Gratn
- License Information
-
More Information
Article History
Received: 1 June 2025
Revised: 26 March 2026
Accepted: 13 April 2026
First Online: 27 April 2026
Competing interests
: GL is an employee of, and JL and IF are founding directors of Ocumetra, a company with interest in clinical tools to assist myopia management.
: The MOSAIC, WA-ATOM, and MTS1 studies all adhered to the tenets of the Declaration of Helsinki, were approved by respective Human Research Ethics Committees [ , , ] and were prospectively registered with clinical trial databases (EudraCT2016-003340-37, ACTRN12617000598381 and NCT03334253). Parents or caregivers provided written informed consent in all cases and participants provided verbal (WA-ATOM) or, where able, written (MOSAIC, MTS1) assent prior to commencing in each study.
